INTEGRATED BIOPHARMA INC: Results of Operations and Financial Condition, Amendment or Waiver of Code of Ethics, Financial Statements and Schedules (Form 8-K)

Section 2.02. Results of Operations and Financial Condition.

On May 12, 2022, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. A copy of the press release is provided as Exhibit 99.1 hereto and is incorporated by reference into this Section 2.02.

The information in this Section 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the obligations of this section. nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Section 5.05. Amendments or Changes to the Company’s Code of Ethics.

On May 11, 2022, the company has updated its Code of Conduct and Ethics Policy to include new sections, including but not limited to Foreign Corrupt Practices and Anti-Corruption Provisions, as well as updating other sections contained in the policy. The updated policy is filed as Exhibit 14.1 hereto and is hereby incorporated by reference into this Section 5.05.

Item 9.01 Financial statements and supporting documents.

(d) Exhibits.

Exhibit 99.1 relating to section 2.02 is deemed to have been furnished and not filed:

14.1     Code of Conduct and Ethics
99.1     Press Release dated May 12, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


————————————————– ——————————

© Edgar Online, source Previews

Comments are closed.